Find a Biotech job in Boston

Genzyme gives up on phosphate drug

WASHINGTON - Genzyme Corp. said it will abandon development of a drug to lower phosphorus levels in the blood after the medicine failed to work better than a current product. (Boston Globe, 11/18/09)

Genentech, Biogen get FDA request on Rituxan

Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration has asked for more information before considering approving Rituxan as a leukemia treatment. (AP, 11/18/09)

Genzyme ends development of Renvela successor

Genzyme Corp. said Wednesday it is canceling development of a successor to its kidney treatment Renvela, as the new drug did not work much better than Renvela. (AP, 11/18/09)

FDA won’t give its OK until Genzyme corrects deficiencies

Genzyme Corp. yesterday said US regulators are delaying approval of Lumizyme, its drug to treat the rare genetic disorder Pompe disease in adults, until the Cambridge biotechnology company solves persistent problems at its cell culture manufacturing plant in Allston. (Boston Globe, 11/16/09)

CombinatoRx dives on FDA rejection

NEW YORK - CombinatoRx Inc. shares fell 46 percent after US regulators rejected an application for the experimental painkiller Exalgo. (Boston Globe, 11/16/09)